Step-therapy edits for PPIs and COX-2 drugs. What we do and do not know.
Frederic R
FR
Curtiss
D003362:Cost-Benefit Analysis; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008565:Membrane Proteins; D010593:Pharmaceutical Services / Q000191:economics* / Q000458:organization & administration; D011451:Prostaglandin-Endoperoxide Synthases; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000191:economics* / Q000627:therapeutic use
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases